EDX Medical’s New Advanced Bowel Cancer Testing Service to Launch in UK to Improve Early Detection

EDX Medical Group announces the commercial launch in the UK of a new comprehensive testing service that improves the early detection of bowel cancer.
Medscape

Nurse-led IBD Care Cuts Hospital Burden, Improves Patient Satisfaction

An IBD care pathway using nurse-led triage and rapid intestinal ultrasound reduces hospital visits, achieves significant cost ...
Medscape

Inflammatory Bowel Disease and Increased BMI May Have Causal Effects on Hidradenitis Suppurativa Risk

Inflammatory bowel disease and elevated BMI may play causal roles in hidradenitis suppurativa, results of a Mendelian ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...
SWI swissinfo.ch

Swiss parliament rejects defence contractor inquiry

The House of Representatives rejected two initiatives tabled by the Social Democrats and the Greens following the publication ...
Le Lézard

Cutera® Announces New FDA Clearances for truFlex® to Support Rehabilitation, Recovery and Muscle Wellness

CUTERA, INC., a leading provider in aesthetic, dermatological solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted expanded indications for its truFlex muscle ...
Morning Overview on MSN

Harvard gut discovery could change how we treat obesity + diabetes

Scientists have long suspected that the trillions of microbes in our intestines quietly steer our weight and blood sugar, but ...
Le Lézard

Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...